<DOC>
	<DOC>NCT03013218</DOC>
	<brief_summary>A phase 1, dose escalation study of ALX148 in patients with advanced solid tumors and lymphoma</brief_summary>
	<brief_title>A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma</brief_title>
	<detailed_description>This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 110 adult patients are expected to be enrolled in the study.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available; or relapsed or refractory NonHodgkin lymphoma for whom no standard therapy is available. Adequate Bone Marrow Function. Adequate Renal &amp; Liver Function. Adequate Performance Status Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids. Previous highdose chemotherapy requiring stem cell rescue. Prior irradiation to &gt;25% of the bone marrow. Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>CD47</keyword>
	<keyword>SIRPÎ±</keyword>
	<keyword>ALX148</keyword>
</DOC>